Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Awad

Showing results (71-80 of 210) with videos related to

Pageof 21
Sort By:
Genome Medicine|April 16, 2022
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histologyElio Adib, Amin H Nassar, Sarah Abou Alaiwi, et al.
American Journal of Human Genetics|June 15, 2006
DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathyMark M Awad, Darshan Dalal, Eunpi Cho, et al.
Oncotarget|December 2, 2017
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancerMark M Awad, Cristina Mastini, Rafael B Blasco, et al.
Cancer|September 3, 2021
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancerSuresh S Ramalingam, Eddie Thara, Mark M Awad, et al.
NPJ Precision Oncology|March 7, 2026
Graph neural network modeling of spatial tumor-immune interactions identifies prognostic cellular niches in non‑small cell lung cancerKatharina V Hoebel, James R Lindsay, Jennifer Altreuter, et al.
JCO Precision Oncology|January 7, 2022
Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLCMichael L Cheng, Marina S D Milan, Rubii M Tamen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2018
False-Positive Plasma Genotyping Due to Clonal HematopoiesisYuebi Hu, Bryan C Ulrich, Julianna Supplee, et al.
JCO Oncology Practice|May 14, 2020
Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic ColitisShilpa Grover, Alex B Ruan, Padmavathi Srivoleti, et al.
Cold Spring Harbor Molecular Case Studies|June 2, 2021
Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosisPanieh Terraf, Lynette M Sholl, Matthew S Davids, et al.
JCO Precision Oncology|October 7, 2024
Response to Crizotinib After Entrectinib Resistance in <i>ROS1</i>-Rearranged, <i>MET</i>-Amplified Lung AdenocarcinomaVictor R Vaz, Malini M Gandhi, Biagio Ricciuti, et al.
Pageof 21

Showing results (71-80 of 210) with videos related to

Sort By:
Pageof 21
Genome Medicine|April 16, 2022
Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histologyElio Adib, Amin H Nassar, Sarah Abou Alaiwi, et al.
American Journal of Human Genetics|June 15, 2006
DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathyMark M Awad, Darshan Dalal, Eunpi Cho, et al.
Oncotarget|December 2, 2017
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancerMark M Awad, Cristina Mastini, Rafael B Blasco, et al.
Cancer|September 3, 2021
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancerSuresh S Ramalingam, Eddie Thara, Mark M Awad, et al.
NPJ Precision Oncology|March 7, 2026
Graph neural network modeling of spatial tumor-immune interactions identifies prognostic cellular niches in non‑small cell lung cancerKatharina V Hoebel, James R Lindsay, Jennifer Altreuter, et al.
JCO Precision Oncology|January 7, 2022
Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLCMichael L Cheng, Marina S D Milan, Rubii M Tamen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2018
False-Positive Plasma Genotyping Due to Clonal HematopoiesisYuebi Hu, Bryan C Ulrich, Julianna Supplee, et al.
JCO Oncology Practice|May 14, 2020
Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic ColitisShilpa Grover, Alex B Ruan, Padmavathi Srivoleti, et al.
Cold Spring Harbor Molecular Case Studies|June 2, 2021
Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosisPanieh Terraf, Lynette M Sholl, Matthew S Davids, et al.
JCO Precision Oncology|October 7, 2024
Response to Crizotinib After Entrectinib Resistance in <i>ROS1</i>-Rearranged, <i>MET</i>-Amplified Lung AdenocarcinomaVictor R Vaz, Malini M Gandhi, Biagio Ricciuti, et al.
Pageof 21